loading...| Preferred Name |
Anagrelide |
|
| Synonyms |
ANAGRELIDE Anagrelide anagrelide |
|
| Definitions |
A synthetic quinazoline derivative, Anagrelide reduces platelet production through a decrease in megakaryocyte maturation. Anagrelide inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. At therapeutic doses, it does not influence white cell counts or coagulation parameters. Anagrelide is used for treatment of essential thrombocythemia to reduce elevated platelet counts and the risk of thrombosis. (NCI04) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C28825 |
|
| ALT_DEFINITION |
A drug that is used to decrease the number of platelets in the blood in order to prevent blood clotting. |
|
| CAS_Registry |
68475-42-3 |
|
| CHEBI_ID |
CHEBI:142290 |
|
| Chemical_Formula |
C10H7Cl2N3O |
|
| code |
C28825 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 |
|
| Contributing_Source |
CTRP FDA HemOnc |
|
| DEFINITION |
A synthetic quinazoline derivative, Anagrelide reduces platelet production through a decrease in megakaryocyte maturation. Anagrelide inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. At therapeutic doses, it does not influence white cell counts or coagulation parameters. Anagrelide is used for treatment of essential thrombocythemia to reduce elevated platelet counts and the risk of thrombosis. (NCI04) |
|
| Display_Name |
Anagrelide |
|
| FDA_UNII_Code |
K9X45X0051 |
|
| FULL_SYN |
ANAGRELIDE Anagrelide anagrelide |
|
| Has_Salt_Form | ||
| label |
Anagrelide |
|
| Legacy Concept Name |
Anagrelide |
|
| NCI_Drug_Dictionary_ID |
810702 |
|
| Preferred_Name |
Anagrelide |
|
| prefixIRI |
Thesaurus:C28825 |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0051809 |
|
| subClassOf |